Brain zaps reveal secrets of movement in Parkinson's

NCT ID NCT01682668

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 07, 2026 · Last updated Jul 08, 2026 · Updated 1 time

Summary

This study investigates how a small brain region called the subthalamic nucleus controls movement in both healthy people and those with Parkinson's disease. Researchers will measure brain cell activity and electrical signals during arm movements and walking to understand why movement becomes difficult in Parkinson's and how deep brain stimulation helps. The findings could improve future treatments for movement problems.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
bilateral subthalamic stimulation
What this could lead to
If successful, this could reveal how deep brain stimulation improves movement in Parkinson's disease, potentially leading to better treatments.
What could go wrong
This is an observational and early-phase study focused on understanding brain activity, not a direct treatment trial. Results may not immediately translate into new therapies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 180 people

The number the study aims to enrol. It can still change while the study runs.

Started

Feb 2013

Expected to finish

Aug 2026

An estimate. End dates often move.

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 70 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion criteria for patients who will be operated 1. Diagnosis of idiopathic Parkinson's disease (according to the criteria of the United Kingdom Parkinson's Disease Society Brain Bank) 2. Age between 18 and 70; 3. Motor complications in the form of fluctuations in motor state or dyskinesias induced by dopaminergic therapy, despite medical treatment optimum; 4. Other medical conditions that are stable or do not interfere with the procedure proposed; 5. Excellent responsiveness to levodopa (UPDRS motor score improvement greater than 50% in the acute levodopa test) 6. Brain MRI without abnormality 7. Normality of biological examinations 8. Person who has voluntarily and informedly agreed to participate in the study (signature of a written consent) 9. Patient with social health insurance Criteria for non-inclusion of Parkinsonian patients who will be operated 1. Contraindication to examinations necessary for inclusion 2. Evolutionary psychiatric pathology; 3. Dementia(MMS\<24/30); 4. Patients with a medical condition that makes surgery dangerous neuro-surgical; 5. Bleeding-promoting diseases and laboratory test abnormalities clotting; 6. Existence of contraindications to MRI (cardiac or neural pacemaker, clips ferromagnetic surgeries, implants and metal objects, foreign bodies intraocular, pregnancy, claustrophobia). 7. Taking drugs interfering with coagulation for 1 month before intervention. 8. Persons under guardianship, curatorship or any other administrative or judicial measure deprivation of rights and liberty Selection criteria for non-operated patients 1. Diagnosis of idiopathic Parkinson's disease (according to the criteria of the United Kingdom Parkinson's Disease Society Brain Bank); 2. Age between 18 and 70; 3. Other medical conditions that are stable or do not interfere with the proposed protocol; 4. Presence of axial signs (gait and/or balance disorders) no improved by antiparkinsonian treatment 5. Brain MRI without notable abnormality 6. Normality of biological examinations 7. Person who has voluntarily and informedly agreed to participate in the study (signature of a written consent) 8. Patient with social health insurance Criteria for non-inclusion of non-operated patients 1. Contraindication to examinations necessary for inclusion 2. Progressive psychiatric pathology; 3. Dementia (MMS\<24/30); 4. Existence of contraindications to MRI (cardiac or neural pacemaker, clips ferromagnetic surgeries, implants and metal objects, foreign bodies intraocular, pregnancy, claustrophobia). 5. Persons under guardianship, curatorship or any other administrative or judicial measuredeprivation of rights and liberty Inclusion criteria for group 3 patients (already operated) 1. Diagnosis of idiopathic Parkinson's disease (according to the criteria of the United Kingdom Parkinson's Disease Society Brain Bank); 2. Bilateral deep brain stimulation of the subthalamic nucleus for more than 1 year 3. Age between 18 and 70; 4. Person who has voluntarily and informedly agreed to participate in the study (signature of a written consent) 5. Patient with social health insurance Criteria for non-inclusion of Parkinsonian patients (already operated) 1. Contraindication to examinations necessary for inclusion 2. Evolutionary psychiatric pathology; 3. Dementia(MMS\<24/30); 4. Persons under guardianship, curatorship or any other administrative or judicial measure deprivation of rights and liberty Inclusion criteria for healthy subjects 1. Age between 18 and 70 years old 2. Normal neurological examination 3. Person who voluntarily and informedly agreed to participate in the study (signature of a written consent) 4. Patient with social health insurance Criteria for non-inclusion of healthy subjects 1. Persons under guardianship, curatorship or any other administrative or judicial measure of deprivation of rights and freedom 2. Existence of neurological, orthopedic or psychiatric history 3. Existence of contraindications to MRI (cardiac or neural pacemaker, ferromagnetic surgical clips, implants and metallic objects, foreign bodies intraocular, pregnancy, claustrophobia).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Parkinson's disease are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • CIC-GHPS

    RECRUITING

    Paris, 75013, France

  • Groupe Hospitalier Pitie-Salpêtrière

    RECRUITING

    Paris, PARIS, 75013, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.